Drug-Induced Uveitis Related to Checkpoint Inhibitors and MAP-kinase Inhibitors

Affiliations

• ¹ Internal Medicine and Systemic Diseases Unit, University Hospital Dijon-Burgundy, Dijon, France; Centre Régional de Pharmacovigilance de Bourgogne, University Hospital Dijon-Burgundy, Dijon, France; INSERM CIC-EC 1432, Clinical Investigation Center, University Hospital Dijon-Burgundy, Dijon, France. Electronic address: thomas.thibault@chu-dijon.fr.
• ² Ophthalmology Department, University Hospital, University Hospital Dijon-Burgundy, Dijon, France; INSERM, CIC 1432, Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, University Hospital Dijon-Burgundy, Dijon, France.
• ³ Centre Régional de Pharmacovigilance de Bourgogne, University Hospital Dijon-Burgundy, Dijon, France.
• ⁴ Internal Medicine and Systemic Diseases Unit, University Hospital Dijon-Burgundy, Dijon, France.
• ⁵ Regional Centre of Pharmacovigilance and Pharmacoepidemiology, CHU de Rouen, Rouen, Normandie, France.
• ⁶ Centre de Pharmacovigilance et de Renseignements sur le médicament, CHU de Saint-Etienne, Saint-Etienne, Auvergne-Rhône-Alpes, France.
• ⁷ Service Hospitalo-Universitaire de Pharmaco-Toxicologie, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France.
• ⁸ Internal Medicine and Systemic Diseases Unit, University Hospital Dijon-Burgundy, Dijon, France; INSERM CIC-EC 1432, Clinical Investigation Center, University Hospital Dijon-Burgundy, Dijon, France.